A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Have T2DM (per World Health Organization [WHO] Classification of Diabetes) not
treated with insulin.

- Have had diabetes for at least 1 year.

- Have been receiving at least 2 oral antihyperglycemic medications (OAMs) for at least
3 months prior to the study.

- Have hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central lab at
screening.

- Have body mass index (BMI) ≤40 kilogram/square meter (kg/m^2).

- This inclusion criterion applies to females of child-bearing potential (not
surgically sterilized and between menarche and 1-year postmenopausal) only: are not
breastfeeding, test negative for a serum pregnancy test, intend not to become
pregnant during study or willing to have a reliable method of birth control.

Exclusion Criteria:

- Insulin therapy: have used insulin therapy (outside of pregnancy) anytime in the past
2 years, except for short-term treatment of acute conditions, and up to a maximum of
4 continuous weeks. Insulin use of any duration during pregnancy is not considered an
exclusion criterion.

- Concomitant medications: rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1)
receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) used
concurrently or within 3 months prior to screening.

- Local OAM restrictions: for participants on OAMs, restrictions for cardiac, renal,
hepatic diseases and maximum dose, local product regulations must apply.

- Weight loss medications: are currently taking, or have taken within the 3 months
preceding screening, prescription or over-the-counter medications to promote weight
loss.

- Severe hypoglycemia history: have had any episodes of severe hypoglycemia within 6
months prior to screening.

- Diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar nonketotic coma (HHNKC):
have had 1 or more episodes of DKA or hyperosmolar state/coma in the past 6 months.

- Cardiovascular: have cardiac disease with functional status that is New York Heart
Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease
Classification).

- Renal: have a history of renal transplantation, or are currently receiving renal
dialysis or have serum creatinine ≥2 milligram/deciliter (mg/dL) (177 micromole/liter
[mol/L]).

- Hepatic: have obvious clinical signs or symptoms of liver disease (excluding
non-alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic
steatohepatitis (NASH), or elevated liver enzyme measurements.

- Lipid-lowering medications:

- Are using niacin preparations as a lipid-lowering medication or bile acid
sequestrants within 90 days prior to screening; or,

- Are using lipid-lowering medication at a dose that has not been stable for ≥90
days prior to screening.